Log in to search using one of your social media accounts:

This page shows you the latest items in this publication.

340B Spotlight: 340B hospitals continue to benefit from consolidation at expense of patients
As we ’ve noted before, incentives to profit under the 340B program are leading to an uneven playing field for providers and may be shifting care to more expensive and less convenient settings in some cases. Roughly45 percent of Medicare acute care hospitals participate in 340B. Many of these hospitals have expanded their reach by buying community-based physician practices and then obtaining 340B discounts for prescriptions written by those physicians.  (Source: The Catalyst)
Source: The Catalyst - April 27, 2017 Category: Pharmaceuticals Tags: 340B hospitals 340B Spotlight Policy Solutions Market Distortions Source Type: news

A new era in genomics
Personalized medicine has taken on a new meaning with the mapping of the human genome. (Source: The Catalyst)
Source: The Catalyst - April 26, 2017 Category: Pharmaceuticals Tags: Research and Development New Era of Medicine GoBoldly Source Type: news

Australia is making it harder to protect inventions. That ’s bad for American businesses and jobs.
Bringing a single new medicine to market requires substantial resources over many years. To ensure continued investment in the development of tomorrow ’s breakthrough treatments and cures, innovators must be able to protect and enforce patents and other intellectual property. (Source: The Catalyst)
Source: The Catalyst - April 25, 2017 Category: Pharmaceuticals Authors: Jay Taylor Tags: Patents Intellectual Property trade Policy Solutions Source Type: news

Medicare Monday: Stakeholders raise concern with MedPAC ’s proposed changes to drug purchasing program
A couple weeks ago, we looked at what a broad group of stakeholders have said about the recommendedchanges to Part B that the Medicare Payment Advisory Commission (MedPAC) voted in support of. But this week, we wanted to examine one proposed change a bit more. (Source: The Catalyst)
Source: The Catalyst - April 24, 2017 Category: Pharmaceuticals Tags: Medicare Medicare Monday Part B Source Type: news

The risks of counterfeit imported medicines
A recentWall Street Journal article laid out the serious concerns posed by potent, counterfeit prescription opioids pouring into the United States from China, Mexico and Canada. The Drug Enforcement Administration (DEA) and other U.S. law enforcement face a growing challenge in preventing counterfeit fentanyl from reaching the United States. Fentanyl is exponentially more powerful than morphine and heroin. Its use is generally limited to use in the management of breakthrough pain in cancer patients – but now hundreds of thousands of pills produced in China are illegally flowing into the United States through Canada and M...
Source: The Catalyst - April 20, 2017 Category: Pharmaceuticals Tags: Counterfeit Drugs Imported Drugs Source Type: news

Fighting disease Together: New ads feature patients and the researchers behind today ’s breakthroughs
Today, we launched our next wave of advertising as part of the GOBOLDLY™ campaign, titledTogether, featuring the stories of researchers developing cutting-edge breakthroughs alongside patients fighting for their lives with the help of biopharmaceutical innovation. (Source: The Catalyst)
Source: The Catalyst - April 19, 2017 Category: Pharmaceuticals Tags: diabetes ALS Alzheimer's cancer Patients Hepatitis C heart disease New Era of Medicine GoBoldly Source Type: news

Trading fair means upholding the law: A focus on patents
Patents are the linchpin of innovation. In the United States and other countries around the world, they provide temporary protection for new inventions. A fair, stable and predictable patent system is the engine of the leading-edge U.S. biopharmaceutical industry, which produces $1.2 trillion in annual economic output and supports 4.5 million jobs across America. (Source: The Catalyst)
Source: The Catalyst - April 18, 2017 Category: Pharmaceuticals Authors: Jay Taylor Tags: Intellectual Property 301 Report trade Policy Solutions Source Type: news

Mental health in the New Era of Medicine
Research and development of innovative medicines to promote mental health are a priority for America ’s biopharmaceutical research companies. Withmore than 130 medicines in development for mental illness, biopharmaceutical scientists are making discoveries in the lab that put treatments in the hands of patients. (Source: The Catalyst)
Source: The Catalyst - April 18, 2017 Category: Pharmaceuticals Authors: Bill Chin, M.D. Tags: Mental Health GoBoldly Source Type: news

New nonprofit – I-ACT for Children – launches to promote innovative medicines development for young patients in need
In an exciting step forward to support research and development of innovative new medicines and devices for pediatric patients, the Critical Path Institute (C-Path)announced the launch of a new nonprofit to address challenges in bringing new therapies to children in need. (Source: The Catalyst)
Source: The Catalyst - April 17, 2017 Category: Pharmaceuticals Authors: Lucy Vereshchagina Tags: Patents Source Type: news

Driving innovation through collaboration
Anew report from Deloitte examines the changing landscape of biopharmaceutical research, as stakeholders across the R&D ecosystem are increasingly coming together to tackle sciences ’ most vexing health challenges. (Source: The Catalyst)
Source: The Catalyst - April 17, 2017 Category: Pharmaceuticals Tags: Research and Development clinical research case studies Source Type: news

Medicare Monday: Another example of the competitive market at work in Part D
Hepatitis C is a devastating viral disease that can result in life-threatening and costly complications. Five years ago, the only available treatment for the disease often resulted in debilitating side effects and only cured half of patients – but thanks tonew cures, cure rates have skyrocketed to upwards of 90 percent. Many patients are able to access these lifesaving medicines through the Medicare Part D program. (Source: The Catalyst)
Source: The Catalyst - April 17, 2017 Category: Pharmaceuticals Tags: Part D Medicare Medicare Monday Hepatitis C Source Type: news

Enforcing unmet trade obligations protects U.S. innovation
The United States leads the world in medical innovation, helping patients across the globe access the latest life-saving treatments and cures. Trade agreements with other nations serve as the foundation of this mutually beneficial arrangement by ensuring that trade partners protect confidential information, prevent patent infringement, and fulfill their obligations fairly. (Source: The Catalyst)
Source: The Catalyst - April 11, 2017 Category: Pharmaceuticals Authors: Jay Taylor Tags: Intellectual Property 301 Report trade Policy Solutions Source Type: news

Medicare Monday: What they are saying about MedPAC ’s Part B recommendations
Last week, the Medicare Payment Advisory Commission (MedPAC) voted on a number of recommendations affecting Medicare Part B. These proposed changes could negatively impact patients ’ access to Part B medicines that are used to treat complex and serious conditions, like cancer, rheumatoid arthritis and mental illness, among others. In case you missed it, we looked at theserecommendations ahead of the vote. (Source: The Catalyst)
Source: The Catalyst - April 10, 2017 Category: Pharmaceuticals Tags: Medicare Medicare Monday Part B Source Type: news

This is not a special effect: New video shows the destruction of a rogue cell
In the latest video of ourCells series, part of the GOBOLDLY ™ campaign, we witness the destruction of a rogue cell that causes rheumatoid arthritis (RA), a disease that affects 1.3 million Americans. (Source: The Catalyst)
Source: The Catalyst - April 10, 2017 Category: Pharmaceuticals Tags: Rheumatoid Arthritis GoBoldly Source Type: news

12 years of the Partnership of Prescription Assistance
Today, the Partnership for Prescription Assistance (PPA) iscelebrating 12 years of helping connect patients who struggle with affordable access to the medicines they need. Because PPA serves as a clearinghouse for more than 475 patient assistance programs (including nearly 200 offered by biopharmaceutical companies), it has served and will continue to to do as a necessary bridge for those who need a helping hand. (Source: The Catalyst)
Source: The Catalyst - April 5, 2017 Category: Pharmaceuticals Tags: PPARX Source Type: news

RA medicines often demonstrate far greater benefits to patients than initially understood
In thelast decade, new therapies to treat rheumatoid arthritis (RA), a progressive and painful autoimmune disorder, have expanded patients ’ treatment options and significantly improved outcomes, helping people with RA achieve disease remission, avoid disability and experience an improved quality of life. And since the approval of these therapies and biologics, clinical evidence has grown, and these treatments are demonstrating far g reater benefits to patients than understood at the time of their initial approval. (Source: The Catalyst)
Source: The Catalyst - April 5, 2017 Category: Pharmaceuticals Tags: Value Rheumatoid Arthritis Value-Driven Health Care The Value Collaborative Source Type: news

NAFTA tribunal fails to rule on Canada ’s patent utility doctrine
While Canada may have prevailed in the recent North American Free Trade Agreement (NAFTA) tribunal case against Eli Lilly, the promise utility doctrine continues to harm their economy. And, unfortunately, that message likely will be lost. The Canadian government and its anti-intellectual property allies are claiming that the NAFTA tribunal endorsed the patent utility doctrine, striking a clear blow to Lilly ’s contention that revocation of their patents was unjustified. In fact, the NAFTA tribunal made no such claim. The three-judge panel instead only ruled that Lilly had not met the threshold requirement of sh...
Source: The Catalyst - April 4, 2017 Category: Pharmaceuticals Tags: Intellectual Property trade Source Type: news

ICYMI: Report highlights overall decrease in cancer death rates
In case you missed it, cancer death rates are continuing to decrease for men, women and children in the United States thanks in part to biopharmaceutical innovation, according to theAnnual Report to the Nation on the Status of Cancer. (Source: The Catalyst)
Source: The Catalyst - April 3, 2017 Category: Pharmaceuticals Tags: cancer Source Type: news

Medicare Monday: A guide to MedPAC ’s Part B vote this week
The Medicare Payment Advisory Commission (MedPAC) is an independent congressional agency that advises Congress on issues related to the Medicare program, including payment, access to and quality of care. You can learn more about MedPAChere. (Source: The Catalyst)
Source: The Catalyst - April 3, 2017 Category: Pharmaceuticals Tags: Medicare Medicare Monday Part B Source Type: news

New analysis: More than half of patients ’ out-of-pocket spending for brand medicines is based on full list price
More than half of commercially insured patients ’ out-of-pocket spending for brand medicines is based on full list prices, according to anew analysis from Amundsen Consulting, a division of QuintilesIMS. Even though rebates paid by biopharmaceutical companies can substantially reduce the prices insurers and pharmacy benefit managers (PBMs) pay for brand medicines, insurers use list prices —rather than discounted prices—to determine how much to charge patients with deductibles and coinsurance. The newly released data show cost sharing for nearly one in five brand prescriptions filled in the commercial market is based ...
Source: The Catalyst - March 29, 2017 Category: Pharmaceuticals Tags: drug cost out of pocket costs Value-Driven Health Care Source Type: news

Resources for understanding the dangers of drug importation
Recent proposals to allow drug importation from other countries aredangerous for patients and the U.S. drug supply chain. To better understand how these importation schemes could negatively affect U.S. patients, here are some of the latestresources to keep in your back pocket: (Source: The Catalyst)
Source: The Catalyst - March 28, 2017 Category: Pharmaceuticals Tags: Safety Drug Importation Counterfeit Source Type: news

ICYMI: Survey highlights key barriers limiting number and scale of new approaches to paying for medicines
In recent years we have seen remarkable scientific breakthroughs in the discovery of new therapies to treat some of the most challenging diseases faced by patients. These groundbreaking medicines have the power to change and save lives, but to help ensure patients have affordable access to these therapies, we need a payment system as innovative as today ’s medicines. (Source: The Catalyst)
Source: The Catalyst - March 27, 2017 Category: Pharmaceuticals Tags: Alternative Payment Models Payment and Delivery Reform FDA Modernization Source Type: news

Medicare Monday: A discussion on affordability and access to medicines
In case you missed it, theAmerican Society on Aging held its annual conference last week in Chicago, IL, where Lori Reilly, PhRMA executive vice president of policy, research& membership, spoke about the importance of ensuring patients have affordable access to treatments. Reilly also recently wrote a piece inAging Today, titled “America must innovate for the health of its aging population.” An excerpt of the piece follows: (Source: The Catalyst)
Source: The Catalyst - March 27, 2017 Category: Pharmaceuticals Tags: Patients Part D Medicare Medicare Monday Medication Adherence Source Type: news

17 years (and more) of medical discoveries
Someone asked me recently if donated kidneys last forever. It ’s been 17 years and a few days since I received one, which has lasted 17 years longer than I thought it would. That may not be forever, but we’re doing pretty well so far.None of it would be possible without medical advancements. (Source: The Catalyst)
Source: The Catalyst - March 24, 2017 Category: Pharmaceuticals Authors: Priscilla VanderVeer Tags: Patients Kidney Disease Source Type: news

ICYMI: What the experts are saying about importation
Voices throughout the U.S. and Canadian health care systems have raised concerns about proposed large-scale drug importation schemes. Former government officials, pharmacy groups and experts have called attention to the potential dangers associated with these importation schemes, as well as the lack of cost savings for American patients. Here ’s a look at what they’re saying: (Source: The Catalyst)
Source: The Catalyst - March 23, 2017 Category: Pharmaceuticals Tags: Imported Drugs Source Type: news

Guest Post: The importance of a modern FDA in drug discovery
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today.We are pleased to share a blog post that was written by Jim Robinson, President, Astellas Americas, and originally published onThe Astellas Way. (Source: The Catalyst)
Source: The Catalyst - March 22, 2017 Category: Pharmaceuticals Authors: Guest Contributor Tags: FDA PhRMA Member Company PDUFA FDA Modernization Source Type: news

Medicare Monday: Billing code basics for biologics in Part B
We ’ve explored the Centers for Medicare& Medicaid Services ’ (CMS) flawed policy for reimbursing biologic and biosimilar productsbefore. Today, we ’re exploring how proposals from MedPAC would build on this flawed approach and put access to these important medicines at risk. (Source: The Catalyst)
Source: The Catalyst - March 20, 2017 Category: Pharmaceuticals Tags: Medicare Medicare Monday Biologics and Biosimilars Part B Source Type: news

How drug importation schemes could increase U.S. law enforcement burdens
In recent weeks, we ’ve explored some of thedangers of importation for patients and how medicines purchased online can be fake. But what would importation schemes mean for U.S. law enforcement? (Source: The Catalyst)
Source: The Catalyst - March 16, 2017 Category: Pharmaceuticals Tags: Safety imported Drugs Source Type: news

Medicare Monday: A closer look at Part B spending
Earlier this month,MedPAC discussed Part B drug spending growth but neglected to put this information in the context of overall program spending. Spending on Part B medicines continues to be a small and stable share of spending. Here are the facts. (Source: The Catalyst)
Source: The Catalyst - March 13, 2017 Category: Pharmaceuticals Tags: Medicare Medicare Monday Part B Source Type: news

Stakeholders Agree: Modernize the legal framework to support move to value-driven health care
Modernizing certain laws and regulations to support the move to value-drive health care is an important step in moving our health care system forward. As part of PhRMA ’s proactive policy solutions, we’verecommended modernizing of the Anti-Kickback Statute to support expanded value-based contracting between biopharmaceutical companies and private payers or health care providers.  (Source: The Catalyst)
Source: The Catalyst - March 6, 2017 Category: Pharmaceuticals Tags: Value-Driven Health Care Policy Solutions Source Type: news

Medicare Monday: New study further confirms increased use of generics after Part D
OnMedicare Monday, we ’ve talked a lot about how things have changed since 2006 and the implementation of Part D. We’ve looked at howPart D costs less than originally projected, howpremiums have remained steady and howcompetition has worked to keep costs low. (Source: The Catalyst)
Source: The Catalyst - March 6, 2017 Category: Pharmaceuticals Tags: Part D Medicare Medicare Monday Source Type: news

Guest Post: Room for optimism in ALS research
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today. (Source: The Catalyst)
Source: The Catalyst - March 3, 2017 Category: Pharmaceuticals Authors: Guest Contributor Tags: Rare Diseases Source Type: news

Guest Post: Debra of America on Epidermolysis Bullosa
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today.We are pleased to host a Q&A with Brett Kopelan, executive director for Debra of America. (Source: The Catalyst)
Source: The Catalyst - March 3, 2017 Category: Pharmaceuticals Authors: Guest Contributor Tags: Rare Diseases Source Type: news

Guest Contributor: Debra of America on Epidermolysis Bullosa
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today.We are pleased to host a Q&A with Brett Kopelan, executive director for Debra of America. (Source: The Catalyst)
Source: The Catalyst - March 3, 2017 Category: Pharmaceuticals Authors: Guest Contributor Tags: Rare Diseases Source Type: news

Guest Post: A Cure for Ellie on Leukodystrophy-LBSL
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today.We are pleased to host a Q&A with Beth McGinn, operator of “A Cure for Ellie,” a non-profit foundation named for her eight-year old daughter. A Cure for Ellie supports cut...
Source: The Catalyst - March 2, 2017 Category: Pharmaceuticals Authors: Guest Contributor Tags: Rare Diseases Source Type: news

Case Study: How one online pharmacy knowingly endangered U.S. consumers
We recently looked atwhat actually happens when a patient orders a medicine through an online Canadian pharmacy and how the product delivered may not be what the patient ordered. Today, we ’re taking it one step further and looking at a real example of one online pharmacy that was caught selling counterfeit medicines to U.S. consumers. (Source: The Catalyst)
Source: The Catalyst - March 2, 2017 Category: Pharmaceuticals Tags: Safety Counterfeit Drugs imported Drugs Source Type: news

Guest Post: Epilepsy Foundation on rare diseases
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today.We are pleased to host a Q&A with Angela Ostrom, chief legal officer& vice President public policy for the Epilepsy Foundation. (Source: The Catalyst)
Source: The Catalyst - March 1, 2017 Category: Pharmaceuticals Authors: Guest Contributor Tags: Rare Diseases Source Type: news

How innovative medicines are benefiting countries across the globe
It is important to look at costs across health care systems to fully understand how life-changing medicines are providing a more sustainable path forward. Across the globe, medicines are allowing patients to lead healthier and more productive lives while also yielding significant cost savings. (Source: The Catalyst)
Source: The Catalyst - March 1, 2017 Category: Pharmaceuticals Tags: drug cost Source Type: news

Why drug importation threatens patient safety
Counterfeit drug manufacturing and trafficking is a multi-billion dollar business. Legislative proposals to allow importation of potentially counterfeit and substandard drugs into the United States are unsafe and put American patients at risk. This is because the U.S. government cannot guarantee that medicines entering the country via importation schemes will meet our strict safety standards. Here ’s a closer look at why these proposals put patient safety at risk: (Source: The Catalyst)
Source: The Catalyst - February 28, 2017 Category: Pharmaceuticals Tags: Safety Counterfeit Drugs imported Drugs Source Type: news

Rare Disease Day: Accelerating innovation for patients in need
As we celebrate Rare Disease Day, it is important to not only reflect on how far we have come in tackling these devastating and complex conditions, but how much unmet medical remains. While more than 7,000 rare diseases have been identified, only 5 percent have treatments. As the majority of these diseases are life threatening, these facts underscore the need for new medicines. (Source: The Catalyst)
Source: The Catalyst - February 28, 2017 Category: Pharmaceuticals Authors: Anne McDonald Pritchett, PhD Tags: Rare Diseases Source Type: news

Medicare Monday: There ’s an agency called MedPAC?
Now that we ’ve learned more aboutIPAB andCMMI, there ’s one more agency on our list to read up on this month – the Medicare Payment Advisory Commission (MedPAC). (Source: The Catalyst)
Source: The Catalyst - February 27, 2017 Category: Pharmaceuticals Tags: Medicare Medicare Monday Source Type: news

Fact Check Friday: The truth about drug importation and patient safety
This week on Fact Check Friday, we ’re discussing the truth about proposals to allow the importation of medicines from other countries and what these proposals mean for patients.MYTH:Importation is safe.FACT:Importation is dangerous for U.S. patients. (Source: The Catalyst)
Source: The Catalyst - February 24, 2017 Category: Pharmaceuticals Tags: Safety Importation Source Type: news

How do multiple sclerosis patients define value?
There are crucial conversations occurring in the health care system about how value is defined. To explore how multiple sclerosis (MS) patients, providers and payers view value,Real Endpoints conducted research that found significant variability in treatment preferences among MS patients, as well as a difference in how patients define value in MS therapies compared to payers and physicians. (Source: The Catalyst)
Source: The Catalyst - February 24, 2017 Category: Pharmaceuticals Tags: Patients chronic disease Multiple Sclerosis Value-Driven Health Care Policy Solutions Source Type: news

PPA: 2016 in review
More than a decade has passed since the Partnership for Prescription Assistance (PPA) launched. In this time, PPA has helped nearly 10 million patients through its free and confidential program, but last year was a particularly special year for the program. (Source: The Catalyst)
Source: The Catalyst - February 23, 2017 Category: Pharmaceuticals Tags: PPA PPARX Source Type: news

ICYMI: New era of medicine initiative kicks off in Boston
It ’s no secret that Boston, Massachusetts is home to many of the most groundbreaking advancements in medical discovery. That’s why yesterday, PhRMA sponsored its first national health care dialogue series focusing on the new era of medicine. The event, convened byThe Atlantic, titled, “Through the Microscope: Examining Modern Medicine, ” explored the transformation of patient care and the science that has revolutionized medical breakthroughs, new treatments and technologies, as well as the investments needed for future innovation. (Source: The Catalyst)
Source: The Catalyst - February 22, 2017 Category: Pharmaceuticals Tags: Innovation Patients Source Type: news

Exploring the new era of medicine
We are in a new era of medicine where innovations are transforming our ability to attack the cause of disease, not just the symptoms. Where treatment decisions are increasingly focused on the needs of the individual patient and where science fiction is now becoming a reality. (Source: The Catalyst)
Source: The Catalyst - February 21, 2017 Category: Pharmaceuticals Authors: Bill Chin, M.D. Tags: Innovation member companies Drug Development Source Type: news

Medicare Monday: Have you heard of CMMI?
(Source: The Catalyst)
Source: The Catalyst - February 20, 2017 Category: Pharmaceuticals Tags: Medicare Medicare Monday CMMI Source Type: news

ICYMI – 3 new reports show dramatic slowdown in medicine spending growth
Newly released government actuary and pharmacy benefit manager data confirm previous projections of a significant decline in medicine spending growth. After accounting for discounts and rebates, medicine spending growth in 2016 dipped into the low single digits, with growth rates between 2 and 5 percent. (Source: The Catalyst)
Source: The Catalyst - February 17, 2017 Category: Pharmaceuticals Tags: drug cost Source Type: news

What you don ’t know about importation from Canada
Proposals to allow the importation of prescription medicines from Canada ignore the dangerous threat to patients of counterfeit and adulterated medicines. What actually happens when a patient orders a medicine through an online Canadian pharmacy may not be what you think. Counterfeit and adulterated medicines may contain paint, drywall or other harmful ingredients, be handled incorrectly or, in some cases, contain no active ingredients at all. Often these medicines look so similar patients cannot tell the difference. This infographic explores the realities of importation, comparing what you think happens in Canada with wha...
Source: The Catalyst - February 17, 2017 Category: Pharmaceuticals Tags: Safety imported Drugs Source Type: news

Biopharmaceutical industry ’s success reducing disparities for African Americans
February is Black History Month, and here at PhRMA, we continue our decades-long commitment to reducing disparities in health care for minorities through developing and helping communities access innovative medicines and cures. (Source: The Catalyst)
Source: The Catalyst - February 16, 2017 Category: Pharmaceuticals Authors: Myisha Gatson Tags: Access Patients HIV/AIDS heart disease Source Type: news